Skip to content
1887

Microbial Genomics logo Microbial Genomics

Volume 11, Issue 6

Genomic analysis of invasive and non-invasive disease-causing isolated from children between 2014 and 2023 in Suzhou, China Open Access

Abstract

In 2017, 553,000 clinical cases of in children were reported in China, although the pneumococcal conjugate vaccine (PCV), which targets the pneumococcal capsule, is not included in the Chinese National Immunization Program (NIP) for children. Therefore, the PCV uptake rate is very low. To investigate the population over the past 10 years in China, we collected 418 S. isolates from children with pneumococcal diseases in Suzhou, China, 2014–2023, and whole-genome sequenced them. A total of 27 serotypes expressed by 36 Global Pneumococcal Sequence Clusters (GPSCs) that encompassed 72 sequence types were identified, with serotype 19F (38.3%, =160) and GPSC1 (60.8%, =254) as the predominant serotype and lineage, respectively. We found that the majority (64.8%, =271) of samples represented serotypes that are covered by the GSK 10-valent PCV (PCV10) formulation and that even more were covered by the SII PCV10 formulation (89.2%, =373). Almost all (94.3%, =394) samples represented serotypes that are included within the 13-valent PCV (PCV13) vaccine formulation. This suggests that the inclusion of the PCV in the NIP would lead to significant benefits for child health. Also, we observed that no significant differences were seen in the serotypes or lineages in cases of invasive and non-invasive pneumococcal diseases.Additionally, we investigated the prevalence of antimicrobial resistance within the population and found that 99.8% (=417) of isolates were predicted to be resistant to at least one antibiotic tested. This again supports the need to increase PCV uptake to prevent infections with antibiotic-resistant and to reduce the number of infections in general, consequently lowering the consumption of antibiotics. In summary, the PCV13 vaccine could potentially cover over 90% of invasive and non-invasive isolates in Suzhou, China. Therefore, increasing the uptake of PCVs by including PCV13 in the NIP would lead to significant benefits for child health.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): Global Pneumococcal Sequencing project , invasive , multidrug resistance , pneumococcal conjugate vaccine (PCV) and Streptococcus pneumoniae
Funding
This study was supported by the:
  • Wellcome Trust (Award 206194)
    • Principle Award Recipient: NotApplicable
  • Bill & Melinda Gates Foundation (Award INV-003570)
    • Principle Award Recipient: NotApplicable
  • National Natural Science Foundation of China (Award 82472322)
    • Principle Award Recipient: MingliangChen
  • National Natural Science Foundation of China (Award 82272381)
    • Principle Award Recipient: MingliangChen
© 2025 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License.
Loading

Article metrics loading...

/content/journal/mgen/10.1099/mgen.0.001398
2025-06-02
2025-06-22
Loading full text...

Full text loading...

/deliver/fulltext/mgen/11/6/mgen001398.html?itemId=/content/journal/mgen/10.1099/mgen.0.001398&mimeType=html&fmt=ahah

References

  1. Lai X, Wahl B, Yu W, Xu T, Zhang H et al. National, regional, and provincial disease burden attributed to Streptococcus pneumoniae and Haemophilus influenzae type B in children in China: modelled estimates for 2010-17. Lancet Reg Health West Pac 2022; 22:100430 [View Article] [PubMed]
     [Google Scholar]
  2. Ning X, Li L, Liu J, Wang F, Tan K et al. Invasive pneumococcal diseases in Chinese children: a multicentre hospital-based active surveillance from 2019 to 2021. Emerg Microbes Infect 2024; 13:2332670 [View Article] [PubMed]
     [Google Scholar]
  3. Wahl B, O’Brien KL, Greenbaum A, Majumder A, Liu L et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15. Lancet Glob Health 2018; 6:e744–e757 [View Article] [PubMed]
     [Google Scholar]
  4. Fu P, Xu H, Jing C, Deng J, Wang H et al. Bacterial epidemiology and antimicrobial resistance profiles in children reported by the ISPED program in China, 2016 to 2020. Microbiol Spectr 2021; 9:e0028321 [View Article] [PubMed]
     [Google Scholar]
  5. von Gottberg A, de Gouveia L, Tempia S, Quan V, Meiring S et al. Effects of vaccination on invasive pneumococcal disease in South Africa. N Engl J Med 2014; 371:1889–1899 [View Article] [PubMed]
     [Google Scholar]
  6. Mackenzie GA, Hill PC, Jeffries DJ, Hossain I, Uchendu U et al. Effect of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease in The Gambia: a population-based surveillance study. Lancet Infect Dis 2016; 16:703–711 [View Article] [PubMed]
     [Google Scholar]
  7. Ladhani SN, Collins S, Djennad A, Sheppard CL, Borrow R et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study. Lancet Infect Dis 2018; 18:441–451 [View Article] [PubMed]
     [Google Scholar]
  8. Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis 2015; 15:301–309 [View Article] [PubMed]
     [Google Scholar]
  9. Weinberger R, von Kries R, van der Linden M, Rieck T, Siedler A et al. Invasive pneumococcal disease in children under 16 years of age: incomplete rebound in incidence after the maximum effect of PCV13 in 2012/13 in Germany. Vaccine 2018; 36:572–577 [View Article] [PubMed]
     [Google Scholar]
  10. Turner P, Leab P, Ly S, Sao S, Miliya T et al. Impact of 13-valent pneumococcal conjugate vaccine on colonization and invasive disease in Cambodian children. Clin Infect Dis 2020; 70:1580–1588 [View Article] [PubMed]
     [Google Scholar]
  11. Zhou L, Yu S, Gao W, Yao K, Shen A et al. Serotype distribution and antibiotic resistance of 140 pneumococcal isolates from pediatric patients with upper respiratory infections in Beijing, 2010. Vaccine 2011; 29:7704–7710 [View Article] [PubMed]
     [Google Scholar]
  12. Song Y, Han Z, Song K, Zhen T. Antibiotic consumption trends in China: evidence from six-year surveillance sales records in Shandong Province. Front Pharmacol 2020; 11:491 [View Article]
     [Google Scholar]
  13. Wang C, Chen Y-H, Fang C, Zhou M, Xu H et al. Antibiotic resistance profiles and multidrug resistance patterns of Streptococcus pneumoniae in pediatrics. Medicine 2019; 98:e15942 [View Article]
     [Google Scholar]
  14. Wang Q, Zhang F-F, Zhao C-J et al. Antimicrobial resistance and serotype distribution of Streptococcus pneumoniae isolated from multi-centers across china. Zhonghua Jie He He Hu Xi Za Zhi 2010; 36:106–112
     [Google Scholar]
  15. Yao K-H, Wang L-B, Zhao G-M, Zheng Y-J, Deng L et al. Pneumococcal serotype distribution and antimicrobial resistance in Chinese children hospitalized for pneumonia. Vaccine 2011; 29:2296–2301 [View Article]
     [Google Scholar]
  16. Dai G, Wang T, He Y, Jiang W, Sun H et al. Antimicrobial susceptibility and serotype distribution of Streptococcus pneumoniae isolates among children in Suzhou, China. Transl Pediatr 2023; 12:2203–2212 [View Article] [PubMed]
     [Google Scholar]
  17. Epping L, van Tonder AJ, Gladstone RA, Bentley SD et al. SeroBA: rapid high-throughput serotyping of Streptococcus pneumoniae from whole genome sequence data. Microb Genom 2018; 4:e000186 [View Article] [PubMed]
     [Google Scholar]
  18. Yahiaoui RY, den Heijer CDJ, Wolfs P, Bruggeman CA, Stobberingh EE. Evaluation of phenotypic and molecular methods for identification of Streptococcus pneumoniae. Future Microbiol 2016; 11:43–50 [View Article] [PubMed]
     [Google Scholar]
  19. Gladstone RA, Lo SW, Lees JA, Croucher NJ, van Tonder AJ et al. International genomic definition of pneumococcal lineages, to contextualise disease, antibiotic resistance and vaccine impact. EBioMedicine 2019; 43:338–346 [View Article] [PubMed]
     [Google Scholar]
  20. Li Y, Metcalf BJ, Chochua S, Li Z, Gertz RE Jr et al. Penicillin-binding protein transpeptidase signatures for tracking and predicting beta-lactam resistance levels in Streptococcus pneumoniae. mBio 2016; 7:e00756-16 [View Article] [PubMed]
     [Google Scholar]
  21. Li Y, Metcalf BJ, Chochua S, Li Z, Gertz RE Jr et al. Validation of β-lactam minimum inhibitory concentration predictions for pneumococcal isolates with newly encountered penicillin binding protein (PBP) sequences. BMC Genomics 2017; 18:621 [View Article]
     [Google Scholar]
  22. Metcalf BJ, Gertz RE Jr, Gladstone RA, Walker H, Sherwood LK et al. Strain features and distributions in pneumococci from children with invasive disease before and after 13-valent conjugate vaccine implementation in the USA. Clin Microbiol Infect 2016; 22:60 [View Article] [PubMed]
     [Google Scholar]
  23. Metcalf BJ, Chochua S, Gertz RE Jr, Li Z, Walker H et al. Using whole genome sequencing to identify resistance determinants and predict antimicrobial resistance phenotypes for year 2015 invasive pneumococcal disease isolates recovered in the United States. Clin Microbiol Infect 2016; 22:1002 [View Article] [PubMed]
     [Google Scholar]
  24. Sanger_SPN_Scripts-Ref. Github. n.d https://github.com/BenJamesMetcalf/Sanger_SPN_Scripts-Ref
  25. CLSI Performance standards for antimicrobial susceptibility testing. In CLSI Supplement M100, 34th Edn Wayne, PA: Clinical and Laboratory Standards Institute; 2024
     [Google Scholar]
  26. Humphries R, Bobenchik AM, Hindler JA, Schuetz AN. Overview of changes to the clinical and laboratory standards institute performance standards for antimicrobial susceptibility testing, M100, 31st edition. J Clin Microbiol 2021; 59:e0021321 [View Article] [PubMed]
     [Google Scholar]
  27. Lees JA, Harris SR, Tonkin-Hill G, Gladstone RA, Lo SW et al. Fast and flexible bacterial genomic epidemiology with PopPUNK. Genome Res 2019; 29:304–316 [View Article]
     [Google Scholar]
  28. GPS: Global Pneumococcal Sequencing Project. n.d https://www.pneumogen.net/gps/training_command_line.html accessed 27 April 2021
  29. J. Page A, Taylor B, A. Keane J. Multilocus sequence typing by blast from de novo assemblies against PubMLST. J Open Source Softw 2016; 1:118 [View Article]
     [Google Scholar]
  30. Price MN, Dehal PS, Arkin AP. FastTree 2--approximately maximum-likelihood trees for large alignments. PLoS One 2010; 5:e9490 [View Article] [PubMed]
     [Google Scholar]
  31. Cohen J. Statistical Power Analysis for the Behavioral Sciences Academic Press; 2013
     [Google Scholar]
  32. Chen K, Zhang X, Shan W, Zhao G, Zhang T. Serotype distribution of Streptococcus pneumoniae and potential impact of pneumococcal conjugate vaccines in China: a systematic review and meta-analysis. Hum Vaccin Immunother 2018; 14:1453–1463 [View Article] [PubMed]
     [Google Scholar]
  33. Zhang T, Zhang J, Shao X, Feng S, Xu X et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against community acquired pneumonia among children in China, an observational cohort study. Vaccine 2021; 39:4620–4627 [View Article] [PubMed]
     [Google Scholar]
  34. Ndlangisa KM, du Plessis M, Lo S, de Gouveia L, Chaguza C et al. A Streptococcus pneumoniae lineage usually associated with pneumococcal conjugate vaccine (PCV) serotypes is the most common cause of serotype 35B invasive disease in South Africa, following routine use of PCV. Microb Genom 2022; 8:000746 [View Article] [PubMed]
     [Google Scholar]
  35. Lekhuleni C, Ndlangisa K, Gladstone RA, Chochua S, Metcalf BJ et al. Impact of pneumococcal conjugate vaccines on invasive pneumococcal disease-causing lineages among South African children. Nat Commun 2024; 15:8401 [View Article] [PubMed]
     [Google Scholar]
  36. Lo SW, Mellor K, Cohen R, Alonso AR, Belman S et al. Global pneumococcal sequencing consortium. Emergence of a multidrug-resistant and virulent Streptococcus pneumoniae lineage mediates serotype replacement after PCV13: an international whole-genome sequencing study. Lancet Microbe 2022; 3:e735–e743 [View Article] [PubMed]
     [Google Scholar]
  37. GBD 2021 Antimicrobial Resistance Collaborators Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050. Lancet 2021; 404:1199–1226
     [Google Scholar]
  38. Laferrière C, Marks M. Chloramphenicol: properties and clinical use. Pediatric Infect Dis 1982; 1:257–264 [View Article]
     [Google Scholar]
  39. Miao C, Yan Z, Chen C, Kuang L, Ao K et al. Serotype, antibiotic susceptibility and whole-genome characterization of Streptococcus pneumoniae in all age groups living in Southwest China during 2018–2022. Front Microbiol 2024; 15:1342839 [View Article]
     [Google Scholar]
  40. Peng S, Ren H, Deng J, Zhao N, Li Y et al. Genotypic and phenotypic characteristics of Streptococcus pneumoniae from community-acquired pneumonia patients and healthy asymptomatic participants in Sichuan province, China. BMC Infect Dis 2021; 21:1030 [View Article] [PubMed]
     [Google Scholar]
  41. World Health Organization Pneumococcal conjugate vaccines: WHO position paper – February 2019. Geneva: World Health Organization; 2019 https://iris.who.int/bitstream/handle/10665/310968/WER9408.pdf accessed 10 March 2025
  42. Liu L, Zhang Z, Zhang X, Xu C, Song Y et al. Coverage of 13-valent pneumococcal conjugate vaccine among children 0–15 months of age — 9 provinces, China, 2019–2021. China CDC Wkly 2023; 5:379–384 [View Article] [PubMed]
     [Google Scholar]
/content/journal/mgen/10.1099/mgen.0.001398
Loading
Genomic analysis of invasive and non-invasive disease-causing Streptococcus pneumoniae isolated from children between 2014 and 2023 in Suzhou, China
M Gen 11, 001398 (2025); https://doi.org/10.1099/mgen.0.001398
/content/journal/mgen/10.1099/mgen.0.001398
/content/journal/mgen/10.1099/mgen.0.001398
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Supplementary material 2

EXCEL

Supplementary material 3

EXCEL

Supplementary material 4

EXCEL

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error